FibroBiologics, Inc. and Charles River Laboratories announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics' technology. This agreement comes ahead of entering into an anticipated master services agreement for the development and manufacture of FibroBiologics's master cell bank, working cell bank, and fibroblast-based spheroids to be utilized in clinical trials. To help advance FibroBiologics?

fibroblast-based therapies into the clinic, Charles River will conduct feasibility studies on FibroBiologics' cell manufacturing processes within its facility. Additionally, contingent upon entering into a master services agreement, Charles River would serve as the contract development and manufacturing organization (CDMO) responsible for producing drug products for certain FibroBiologics? clinical trials.